For example, in trials involving CD52-knockout allogeneic CAR T cells, the anti-CD52 monoclonal antibody alemtuzumab has been incorporated to further eliminate host T and NK cells and reduce the risk of GvHD [200,201,202]. Here, CD52 is linked to graft versus host disease.